Synaptic mitochondrial dysfunction and Alzheimer’s disease: from molecular mechanisms to therapeutic strategies
The ability of AD treatments targeting classic pathological proteins to achieve meaningful clinical outcomes has been severely limited, shifting attention to the earlier upstream pathways that drive disease progression. Increasing evidence indicates that synaptic mitochondrial dysfunction is an earl...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2026-09-01
|
| Colección: | Frontiers in Pharmacology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1849218/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|